{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fnovel-adcs-in-advanced-breast-cancer-2eaTIgyP","width":444,"version":"1.0","type":"rich","title":"Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/942ac3c6-f282-4581-a914-61ed9ac0a91d/6711-breast-her2-low-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/b82558f2-f626-4485-8bc8-eb7fc874a605\" height=\"200\" width=\"100%\" title=\"Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Discussion between experts on novel and emerging HER2-targeted and TROP-2–directed therapies for patients with HER2-low, hormone receptor–positive, and triple-negative advanced breast cancer."}